Scinai Immunotherapeutics

Innovative Immunotherapeutic Treatments

Health Tech & Life Sciences
Acquired by Pincell srl on Jun, 2025

Company Overview

Snapshot

Founded in July 2003, Scinai Immunotherapeutics operates with 11–50 employees and has raised a total of $63.94 million across 12 funding rounds. The company was acquired by Pincell srl in June 2025.

Business overview

Scinai Immunotherapeutics is a biopharmaceutical company specializing in the development, manufacturing, and commercialization of inflammation and immunology (I&I) biological products. The company focuses on treating autoimmune and infectious diseases, leveraging a state-of-the-art facility for biopharmaceutical product development and manufacturing. Scinai offers end-to-end boutique CDMO services while developing its own pipeline, including an innovative nanosized VHH antibody (NanoAb) platform, within the Health Tech & Life Sciences sector.

Strategic signal

Scinai Immunotherapeutics was acquired by Pincell srl in June 2025, signaling a significant strategic exit and integration into a larger entity. This acquisition validates Scinai's biopharmaceutical assets and CDMO capabilities, suggesting a potential for accelerated development and market reach for its innovative immunotherapeutic treatments under new ownership.

Company Intelligence Q&A

What was a significant corporate development for Scinai Immunotherapeutics in June 2025?
In June 2025, Scinai Immunotherapeutics was acquired by Pincell srl.
What was the focus of Scinai Immunotherapeutics' rebranding in September 2023?
In September 2023, BiondVax Pharmaceuticals Ltd. rebranded as Scinai Immunotherapeutics Ltd. to reflect a new focus on developing novel inflammation and immunology (I&I) biological therapeutics.
What was the outcome of the European Investment Bank's review of its financial facility with Scinai Immunotherapeutics in November 2023?
In November 2023, the European Investment Bank (EIB) extended the maturity of its finance facility with Scinai Immunotherapeutics from 2027 to 2031, following Scinai’s strategic pivot.
What grant did Scinai Immunotherapeutics receive in October 2025?
In October 2025, Scinai Immunotherapeutics was awarded a grant from the Israel Innovation Authority to expand its fill and finish CDMO capabilities.
What was the outcome of Scinai Immunotherapeutics' Nasdaq compliance efforts in November 2023?
In November 2023, Scinai Immunotherapeutics regained compliance with Nasdaq's Stockholders' Equity Rule.

External links